Drug Product Impurity Characterization Detailed In CMC Draft Guidance
This article was originally published in The Tan Sheet
Executive Summary
All expected drug product impurities should be disclosed in NDAs and ANDAs, even if they are not considered sufficiently important to affect the drug's approvability, according to a new FDA draft guidance
You may also be interested in...
CMC Comparability Protocols Should Allow For Broader Changes, PhRMA Says
The scope of FDA's chemistry, manufacturing & controls comparability protocols should be broader if sufficient data are available, the Pharmaceutical Research & Manufacturers of America suggests
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC